Teligent, Inc. logo
Teligent, Inc. TLGT

Teligent, Inc. Gross Profit 2011-2026 | TLGT

Gross profit is a key indicator of how efficiently a company produces or sells its products. This metric helps assess a business’s ability to generate revenue at the initial stage, before accounting for all other expenses. Regular analysis of gross profit allows companies to respond in a timely manner to changes in cost of goods, pricing strategy, and market conditions.

Calculation formula:
Gross Profit = Revenue – Cost of Goods Sold (COGS)

Revenue — all cash inflows from the sale of goods or services.
Cost of Goods Sold — direct costs related to the production or acquisition of goods:
  • Raw materials and supplies
  • Wages of production personnel
  • Depreciation of equipment
  • Transportation and warehousing costs (if directly related to production)
Importance for business:
  • Assessing core business profitability
    If gross profit is declining, it may indicate rising production costs or falling sales.
  • Financial planning
    Gross profit is the basis for calculating other key metrics, such as operating and net profit.
  • Benchmarking against competitors
    Gross profit analysis helps compare the efficiency of different companies within the same industry.
  • Insights into pricing effectiveness
    If gross profit is low, the company may be pricing too low or failing to control costs effectively.
Reasons for a decline in gross profit:
  • Increase in raw material and supply costs
  • Rising production expenses
  • Price reductions due to competition
  • Decrease in sales volume
  • Currency exchange rate fluctuations (for imports/exports)

Gross profit is an important metric, but it does not provide a complete picture of a company’s financial health, as it does not account for administrative and selling expenses, taxes, debt burden, or depreciation.

Annual Gross Profit Teligent, Inc.

2020 2019 2018 2017 2016 2015 2014 2013 2012 2011
45.3 M 23.5 M 22.4 M 27.4 M 34.7 M 21.3 M 16.8 M 6.14 M 2.78 M 2.26 M

All numbers in USD currency

Indicator range from annual reports

Maximum Minimum Average
45.3 M 2.26 M 20.3 M

Gross Profit of other stocks in the Biotechnology industry

Issuer Gross Profit Price % 24h Market Cap Country
MorphoSys AG MorphoSys AG
MOR
180 M - 2.43 % $ 254 M germanyGermany
Verastem Verastem
VSTM
14.6 M $ 5.04 -4.73 % $ 349 M usaUSA
VistaGen Therapeutics VistaGen Therapeutics
VTGN
1.34 M $ 0.57 -5.87 % $ 17.6 M usaUSA
Alexion Pharmaceuticals, Inc. Alexion Pharmaceuticals, Inc.
ALXN
5.52 B - - $ 40.3 B usaUSA
Genfit SA Genfit SA
GNFT
5.51 M - 2.54 % $ 160 B franceFrance
Midatech Pharma plc Midatech Pharma plc
MTP
-428 K - -18.52 % $ 27.3 M britainBritain
EyeGate Pharmaceuticals, Inc. EyeGate Pharmaceuticals, Inc.
EYEG
12.1 - -1.52 % $ 24.7 M usaUSA
Aptinyx Aptinyx
APTX
1.56 K - -39.0 % $ 4.57 M usaUSA
Институт стволовых клеток человека Институт стволовых клеток человека
ISKJ
774 M - - - russiaRussia
Adaptive Biotechnologies Corporation Adaptive Biotechnologies Corporation
ADPT
62.8 M $ 12.41 -11.1 % $ 1.88 B usaUSA
Xenon Pharmaceuticals Xenon Pharmaceuticals
XENE
6.83 M $ 54.48 -1.89 % $ 4.24 B canadaCanada
BeiGene, Ltd. BeiGene, Ltd.
BGNE
4.67 B - 0.49 % $ 251 B cayman-islandsCayman-islands
ChemoCentryx ChemoCentryx
CCXI
64.9 M - - $ 3.74 B usaUSA
Enochian Biosciences Enochian Biosciences
ENOB
37.5 K - - $ 40.5 M usaUSA
CureVac N.V. CureVac N.V.
CVAC
-10.6 M - - $ 867 M germanyGermany
Summit Therapeutics Summit Therapeutics
SMMT
56.4 M $ 16.58 -3.94 % $ 12.4 B britainBritain
Alnylam Pharmaceuticals Alnylam Pharmaceuticals
ALNY
195 M $ 317.36 -3.29 % $ 41.6 B usaUSA
Arbutus Biopharma Corporation Arbutus Biopharma Corporation
ABUS
-40.6 M $ 4.29 -3.6 % $ 822 M canadaCanada
Brickell Biotech Brickell Biotech
BBI
1.82 K - -5.38 % $ 6.06 M usaUSA
Ampio Pharmaceuticals Ampio Pharmaceuticals
AMPE
-523 K - -11.43 % $ 502 K usaUSA
Amphastar Pharmaceuticals Amphastar Pharmaceuticals
AMPH
356 M $ 19.01 -2.66 % $ 889 M usaUSA
Завод ДИОД Завод ДИОД
DIOD
325 M - - - russiaRussia
Фармсинтез Фармсинтез
LIFE
160 M - - - russiaRussia
ACADIA Pharmaceuticals ACADIA Pharmaceuticals
ACAD
473 M $ 20.75 -3.35 % $ 3.44 B usaUSA
Aligos Therapeutics Aligos Therapeutics
ALGS
-10.5 M $ 6.66 -5.4 % $ 65.8 M usaUSA
Viela Bio, Inc. Viela Bio, Inc.
VIE
9.61 M - - $ 2.91 B usaUSA
Aravive Aravive
ARAV
5.68 K - -13.39 % $ 1.45 M usaUSA
Alkermes plc Alkermes plc
ALKS
991 M $ 29.39 -1.77 % $ 4.84 B irlandaIrlanda
Cabaletta Bio Cabaletta Bio
CABA
0.006 $ 2.68 -4.96 % $ 269 M usaUSA
AbbVie AbbVie
ABBV
12.1 B $ 209.4 -0.81 % $ 370 B usaUSA
Acer Therapeutics Acer Therapeutics
ACER
1.27 M - 2.71 % $ 14 M usaUSA
Acorda Therapeutics Acorda Therapeutics
ACOR
119 M - -24.86 % $ 820 K usaUSA
Acasti Pharma Acasti Pharma
ACST
-32.3 K - 4.01 % $ 150 M canadaCanada
Adverum Biotechnologies Adverum Biotechnologies
ADVM
2.32 M - - $ 86.2 M usaUSA